Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 7/20 | 0.51 |
| ▸ | PLK1 | P53350 | 4/20 | 0.51 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.39 |
| ▸ | TEC | P42680 | 1/20 | 0.39 |
| ▸ | TXK | P42681 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | BMX | P51813 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182613 | 1.00 | NEK2 (0.51) | NEK2PLK1RPS6KA5ERBB2TEC | |
| SCHEMBL182322 | 0.86 | NEK2 (0.50) | NEK2PLK1RPS6KA5ERBB2TEC | |
| SCHEMBL182323 | 0.86 | NEK2 (0.50) | NEK2PLK1RPS6KA5ERBB2TEC | |
| SCHEMBL12595307 | 0.85 | NEK2 (0.48) | NEK2PLK1RPS6KA5ERBB2TEC | |
| SCHEMBL182601 | 0.85 | NEK2 (0.49) | NEK2PLK1RPS6KA5ERBB2TEC | |
| SCHEMBL182602 | 0.85 | NEK2 (0.49) | NEK2PLK1RPS6KA5ERBB2TEC | |
| SCHEMBL11021837 | 0.84 | NEK2 (0.56) | NEK2PLK1RPS6KA5ERBB2TEC | |
| SCHEMBL11021835 | 0.84 | NEK2 (0.56) | NEK2PLK1RPS6KA5ERBB2TEC | |
| Nitrous Acid SCHEMBL11021890 | 0.78 | NEK2 (0.35) | NEK2PLK1RPS6KA5CYP1A2 | |
| Nitrous Acid SCHEMBL11021891 | 0.78 | NEK2 (0.35) | NEK2PLK1RPS6KA5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| EP-2499124-B1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2499124-B1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9018234-B2 | Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2485726-B1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2485726-B1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
| WO-2011069761-A1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011067189-A2 | CMET INHIBITORS FOR TREATING ENDOMETRIOSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011042368-A1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042367-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042367-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011003604-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010094405-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094405-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2009149836-A1 | ANNELLATED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, ERBB4, RET | NEK2 827/4885PLK1 1039/4885RPS6KA5 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.